| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly demonstrates strong momentum in product development, with recent innovations including an obesity treatment and advancements in diabetes management through drugs like Foundayo and Onswik insulin. The company's commitment to research and development has led to promising FDA approvals, ensuring a solid market presence and potential financial gains. High sentiment scores around products such as Retatrutide further highlight the company's ability to secure a competitive edge. However, the landscape remains challenging with the need for continuous innovation amidst fierce competition. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.9 is bullish. The market sentiment at 1 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1.1, and the negative at -0.1 on 2026-09-25. The forces of Sentiment towards Fundamentals (3.4), Valuation Sentiment (1.2), Stock Price Trend (0.9), Option Sentiment (0.8), Sector Price Trend (0.1), and Market Risk Appetite (0) will drive up the price. The forces of and Price Level Sentiment (-0.5) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-25 | 0%(0%) | 1183.72 | 1.65% | 92 | 63 | 43 | -0.01% | 0.59% | 0.9 | 0.4 | 1.1% | 1 | Long | 55% | 3.4 | -4 |
| 2026-09-24 | 0%(0%) | 1183.79 | 1.6% | 94 | 58 | 59 | 2.7% | 0.53% | 0.8 | 0.2 | 1.2% | 1.8 | Long | 55% | 4.2 | -1 |
| 2026-09-23 | 0%(0%) | 1152.7 | 1.68% | 52 | 47 | 43 | -1.53% | 0.25% | 0 | -0.3 | 0.7% | 1.6 | Short | 55% | 4 | 7 |
| 2026-09-22 | 0%(0%) | 1170.6 | 2.26% | 65 | 55 | 54 | 0.51% | 0.41% | 0.4 | -0 | 0.8% | 1.4 | Long | 55% | 3.8 | -1 |
| 2026-09-21 | 0%(0.1%) | 1164.66 | 2.85% | 54 | 54 | 63 | 1.03% | 0.14% | -0.1 | 0.2 | 0.7% | 1.4 | Long | 55% | 4.2 | 6.3 |
| 2026-09-20 | 0%(0.1%) | -0.2 | 0.2 | 0.7 | 3.8 | -1 | ||||||||||
| 2026-09-19 | 0%(0.1%) | -0.2 | 0.2 | 0.7 | 3.8 | -1 | ||||||||||
| 2026-09-18 | 0%(0.1%) | 1152.73 | 3.41% | 43 | 40 | 58 | 0.04% | -0.06% | -0.2 | 0.2 | 0.4% | 1.3 | Long | 55% | 4.2 | 6.3 |
| 2026-09-17 | 0%(0.1%) | 1152.25 | 3.74% | 41 | 39 | 62 | 1.18% | -0.07% | -0.5 | 0.3 | 0.4% | 0.6 | Wait | 50% | 3.8 | -1 |
| 2026-09-16 | 0%(0.1%) | 1138.8 | 4.34% | 32 | 26 | 44 | 0.16% | -0.18% | -0.5 | -0.1 | 0.4% | 0.5 | Short | 55% | 3.9 | -1 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-09-25 17:04:07 Eli Lilly's advancements in diabetes treatment demonstrate increased competition in the pharmaceutical industry, particularly in the diabetes sector. |
| 2026-09-25 17:04:07 The rising interest from investors in pharmaceutical stocks like Eli Lilly showcases the growing importance of innovative healthcare solutions. |
| 2026-09-25 17:04:07 The slight decline in stock performance suggests a period of stability amidst market fluctuations. |
| 2026-09-25 17:04:07 The discussion around Eli Lilly being a strong growth stock reflects confidence in its future earnings and investment attractiveness. |
| 2026-09-25 17:04:07 Eli Lilly's FDA approval for the once-weekly Onswik insulin demonstrates a significant advancement in product development that should positively impact patients with type II diabetes. |
| 2026-09-25 11:49:00 The $90 million jury verdict represents a significant financial development for Nektar Therapeutics, showcasing the potential for substantial economic impacts resulting from litigation. |
| 2026-09-25 11:49:00 The case underscores the complexities and potential pitfalls in licensing agreements and partnerships within the pharmaceutical sector. |
| 2026-09-25 11:49:00 The lawsuit between Nektar Therapeutics and Eli Lilly highlights the legal disputes that can arise in the biotech industry, impacting business relationships and financial outcomes. |